<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00494871</url>
  </required_header>
  <id_info>
    <org_study_id>12620</org_study_id>
    <nct_id>NCT00494871</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation</brief_title>
  <official_title>Evaluation of the Efficacy and Safety of Rivaroxaban (BAY59-7939) for the Prevention of Stroke and Non-central Nervous System Systemic Embolism in Subjects With Non-valvular Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen R&amp;D, L.L.C.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical study evaluating the efficacy and safety of rivaroxaban for stroke
      prevention in patients with atrial fibrillation (originally described in Japanese).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Within the US 'Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.' is sponsor.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event Rate of the Composite Endpoint of Adjudicated Major Bleeding or Adjudicated Non-major Clinically Relevant Bleeding</measure>
    <time_frame>Up to 2 days after the last dose</time_frame>
    <description>Major bleeding: clinically overt bleeding (COB) associated with a fall in hemoglobin ≥2 g/dL, leading to transfusion ≥2 units of packed red blood cells or whole blood, occurring in a critical site or contributing to death. Non-major clinically relevant bleeding: COB that does not meet the definition of major bleeding, but requires medical intervention or unscheduled contact with the physician, (temporary) discontinuation of the study treatment, discomfort to the subject such as pain, or impairment of activities of daily life.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event Rate of the Composite Endpoint of Adjudicated Stroke and Non-central Nervous System (CNS) Systemic Embolism</measure>
    <time_frame>Up to 2 days after the last dose</time_frame>
    <description>This is the principal efficacy endpoint. Stroke included hemorrhagic, ischemic infarction and unknown. Arterial emboli in the following areas were &quot;non-CNS systemic embolism&quot;: peripheral arterial in the upper and lower extremities, renal, mesenteric, splenic, hepatic, ocular/retinal and others. Pulmonary embolism or myocardial infarction was excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Rate of the Composite Endpoint of Adjudicated Stroke, Non-CNS Systemic Embolism, and Vascular Death</measure>
    <time_frame>Up to 2 days after the last dose</time_frame>
    <description>Stroke included hemorrhagic, ischemic infarction and unknown. Arterial emboli in the following areas were &quot;non-CNS systemic embolism&quot;: peripheral arterial in the upper and lower extremities, renal, mesenteric, splenic, hepatic, ocular/retinal and others. Pulmonary embolism or myocardial infarction was excluded. Any death that was not clearly non-vascular.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Rate of the Composite Endpoint of Adjudicated Stroke, Non-CNS Systemic Embolism, Myocardial Infarction, and Vascular Death</measure>
    <time_frame>Up to 2 days after the last dose</time_frame>
    <description>Stroke included hemorrhagic, ischemic infarction and unknown. Arterial emboli in the following areas were &quot;non-CNS systemic embolism&quot;: peripheral arterial in the upper and lower extremities, renal, mesenteric, splenic, hepatic, ocular/retinal and others. Pulmonary embolism or myocardial infarction was excluded. Myocardial infarction: assessed based on either cardiac biomarkers, new abnormal Q waves appeared on electrocardiogram for ≥2 leads, or autopsy confirmation. Any death that was not clearly non-vascular.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Rate of Stroke</measure>
    <time_frame>Up to 2 days after the last dose</time_frame>
    <description>All events were adjudicated and confirmed by a central independent committee blinded to treatment. Stroke included hemorrhagic (Stroke with local collections of intraparenchymal blood. Subarachnoid hemorrhage, subdural hemorrhage, and epidural hemorrhage were excluded.), ischemic infarction (Stroke without focal collection of intracranial blood) and unknown (No imaging data and anatomic findings were available.).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Rate of Non-CNS Systemic Embolism</measure>
    <time_frame>Up to 2 days after the last dose</time_frame>
    <description>All events were adjudicated and confirmed by a central independent committee blinded to treatment. Non-CNS systemic embolism was abrupt vascular insufficiency associated with clinical or radiological evidence of arterial occlusion in the absence of other likely mechanisms (such as trauma, atherosclerosis, and instrumentation). Arterial emboli in the following areas were &quot;non-CNS systemic embolism&quot;: peripheral arterial in the upper and lower extremities, renal, mesenteric, splenic, hepatic, ocular/retinal and others. Pulmonary embolism or myocardial infarction was excluded from this category.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Rate of Myocardial Infarction</measure>
    <time_frame>Up to 2 days after the last dose</time_frame>
    <description>All events were adjudicated and confirmed by a central independent committee blinded to treatment. Myocardial infarction was assessed based on either cardiac bio-markers (troponin I, troponin T, or creatine kinase-muscle and brain subunit isozyme), new abnormal Q waves appeared on ECG for 2 or more leads, or autopsy confirmation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Rate of Vascular Death</measure>
    <time_frame>Up to 2 days after the last dose</time_frame>
    <description>All events were adjudicated and confirmed by a central independent committee blinded to treatment. Any death that was not clearly non-vascular (e.g., deaths due to spontaneous bleeding, myocardial infarction, stroke, cardiac failure, and arrhythmia)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Rate of Stroke With Serious Residual Disability</measure>
    <time_frame>Up to 2 days after the last dose</time_frame>
    <description>All events were adjudicated and confirmed by a central independent committee blinded to treatment. A stroke was considered disabling if the participant's modified Rankin score was between 3 and 5, inclusive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Rate of All-cause Death</measure>
    <time_frame>Up to 2 days after the last dose</time_frame>
    <description>All events were adjudicated and confirmed by a central independent committee blinded to treatment. All-cause death included vascular death and non-vascular death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Rate of Adjudicated Major Bleeding</measure>
    <time_frame>Up to 2 days after the last dose</time_frame>
    <description>All events were adjudicated and confirmed by a central independent committee blinded to treatment. Major bleeding was clinically overt bleeding associated with a fall in hemoglobin of 2 g/dL or higher, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Rate Adjudicated Non-major Clinically Relevant Bleeding</measure>
    <time_frame>Up to 2 days after the last dose</time_frame>
    <description>All events were adjudicated and confirmed by a central independent committee blinded to treatment. Non-major clinically relevant bleeding was clinically overt bleeding that does not meet the definition of major bleeding, but requires medical intervention or unscheduled contact with the physician, (temporary) discontinuation of the study treatment, discomfort to the subject such as pain, or impairment of activities of daily life.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1280</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban (Xarelto, BAY59-7939)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received once daily (OD) a rivaroxaban 15 mg tablet and a warfarin placebo tablet during the double-blind treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received OD a warfarin potassium tablet and a rivaroxaban placebo tablet during the double-blind treatment period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban (Xarelto, BAY59-7939)</intervention_name>
    <description>Participants orally administered rivaroxaban 15 mg OD (CrCL [creatinine clearance] &gt;= 50 mL/min) or 10 mg OD (CrCL 30-49 mL/min)</description>
    <arm_group_label>Rivaroxaban (Xarelto, BAY59-7939)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Participants orally administered a warfarin potassium tablet (INR [international normalized ratio] target was 1.6-2.6 for patients &gt;70 years and 2.0-3.0 for patients &lt;70 years)</description>
    <arm_group_label>Warfarin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban placebo</intervention_name>
    <description>Participants orally administered a rivaroxaban placebo tablet</description>
    <arm_group_label>Warfarin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin placebo</intervention_name>
    <description>Participants orally administered a warfarin placebo tablet (adjusted based upon sham INR values)</description>
    <arm_group_label>Rivaroxaban (Xarelto, BAY59-7939)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  20 years or older

          -  Japanese male or female

          -  Non- valvular atrial fibrillation documented by ECG

          -  Patients with a risk of stroke and non-CNS systemic embolism

        Exclusion Criteria:

          -  Significant mitral stenosis

          -  Patients in whom anticoagulants are contraindicated
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kasugai</city>
        <state>Aichi</state>
        <zip>487-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>453-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>454-8502</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>455-8530</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>457-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>462-0825</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Okazaki</city>
        <state>Aichi</state>
        <zip>444-8553</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goshogawara</city>
        <state>Aomori</state>
        <zip>037-0053</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hirosaki</city>
        <state>Aomori</state>
        <zip>036-8082</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hirosaki</city>
        <state>Aomori</state>
        <zip>036-8545</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Asahi</city>
        <state>Chiba</state>
        <zip>289-2511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Funabashi</city>
        <state>Chiba</state>
        <zip>274-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Imba</city>
        <state>Chiba</state>
        <zip>270-1694</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Matsudo</city>
        <state>Chiba</state>
        <zip>270-2251</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Matsudo</city>
        <state>Chiba</state>
        <zip>271-0077</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yotsukaido</city>
        <state>Chiba</state>
        <zip>284-0032</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Imabari</city>
        <state>Ehime</state>
        <zip>799-1592</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Matsuyama</city>
        <state>Ehime</state>
        <zip>790-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Matsuyama</city>
        <state>Ehime</state>
        <zip>790-0925</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Matsuyama</city>
        <state>Ehime</state>
        <zip>791-8026</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Niihama</city>
        <state>Ehime</state>
        <zip>792-8543</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saijo</city>
        <state>Ehime</state>
        <zip>793-0030</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toon</city>
        <state>Ehime</state>
        <zip>791-0281</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chikushi-gun</city>
        <state>Fukuoka</state>
        <zip>811-1244</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chikushino</city>
        <state>Fukuoka</state>
        <zip>818-8502</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chikushino</city>
        <state>Fukuoka</state>
        <zip>818-8516</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kasuga</city>
        <state>Fukuoka</state>
        <zip>816-0833</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kasuga</city>
        <state>Fukuoka</state>
        <zip>816-0864</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <zip>800-0057</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <zip>806-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <zip>830-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ogori</city>
        <state>Fukuoka</state>
        <zip>838-0141</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yame</city>
        <state>Fukuoka</state>
        <zip>834-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yame</city>
        <state>Fukuoka</state>
        <zip>834-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Koriyama</city>
        <state>Fukushima</state>
        <zip>963-8052</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ogaki</city>
        <state>Gifu</state>
        <zip>503-8502</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maebashi</city>
        <state>Gunma</state>
        <zip>371-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mebashi</city>
        <state>Gunma</state>
        <zip>371-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Otake</city>
        <state>Hiroshima</state>
        <zip>739-0696</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Asahikawa</city>
        <state>Hokkaido</state>
        <zip>078-8214</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chitose</city>
        <state>Hokkaido</state>
        <zip>066-0034</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hakodate</city>
        <state>Hokkaido</state>
        <zip>040-8611</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Muroran</city>
        <state>Hokkaido</state>
        <zip>051-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Otaru</city>
        <state>Hokkaido</state>
        <zip>047-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>004-0052</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-0061</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8570</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>064-0807</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>064-8570</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>065-0027</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>065-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>065-8611</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sunagawa</city>
        <state>Hokkaido</state>
        <zip>073-0196</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tomakomai</city>
        <state>Hokkaido</state>
        <zip>053-8506</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>651-0073</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>651-1145</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>652-0803</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Higashiibaraki</city>
        <state>Ibaraki</state>
        <zip>311-3193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hitachi</city>
        <state>Ibaraki</state>
        <zip>317-0077</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Joso</city>
        <state>Ibaraki</state>
        <zip>303-0016</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kasama</city>
        <state>Ibaraki</state>
        <zip>309-1793</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moriya</city>
        <state>Ibaraki</state>
        <zip>302-0112</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Namegata</city>
        <state>Ibaraki</state>
        <zip>311-3516</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toride</city>
        <state>Ibaraki</state>
        <zip>302-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <zip>920-8650</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nomi</city>
        <state>Ishikawa</state>
        <zip>923-1100</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hanamaki</city>
        <state>Iwate</state>
        <zip>025-0075</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morioka</city>
        <state>Iwate</state>
        <zip>020-0103</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marugame</city>
        <state>Kagawa</state>
        <zip>763-8502</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Takamatsu</city>
        <state>Kagawa</state>
        <zip>760-0018</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Izumi</city>
        <state>Kagoshima</state>
        <zip>899-0131</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atsugi</city>
        <state>Kanagawa</state>
        <zip>243-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fujisawa</city>
        <state>Kanagawa</state>
        <zip>251-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fujisawa</city>
        <state>Kanagawa</state>
        <zip>251-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kamakura</city>
        <state>Kanagawa</state>
        <zip>247-8533</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa</state>
        <zip>216-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>227-0046</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>231-8682</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>236-0037</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>236-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nangoku</city>
        <state>Kochi</state>
        <zip>783-8509</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uji</city>
        <state>Kyoto</state>
        <zip>611-0042</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kuwana</city>
        <state>Mie</state>
        <zip>511-0068</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>980-0803</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>981-3107</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>983-0821</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>983-8512</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>983-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Komoro</city>
        <state>Nagano</state>
        <zip>384-8588</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Matsumoto</city>
        <state>Nagano</state>
        <zip>390-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suwa</city>
        <state>Nagano</state>
        <zip>392-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Joetsu</city>
        <state>Niigata</state>
        <zip>949-3193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagaoka</city>
        <state>Niigata</state>
        <zip>940-8621</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beppu</city>
        <state>Oita</state>
        <zip>874-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beppu</city>
        <state>Oita</state>
        <zip>874-0901</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yufu</city>
        <state>Oita</state>
        <zip>879-5593</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kasaoka</city>
        <state>Okayama</state>
        <zip>714-0043</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shimajiri</city>
        <state>Okinawa</state>
        <zip>901-0493</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daito</city>
        <state>Osaka</state>
        <zip>574-0074</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Higashiosaka</city>
        <state>Osaka</state>
        <zip>578-8588</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hirakata</city>
        <state>Osaka</state>
        <zip>573-0153</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hirakata</city>
        <state>Osaka</state>
        <zip>573-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kawachinagano</city>
        <state>Osaka</state>
        <zip>586-8521</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kishiwada</city>
        <state>Osaka</state>
        <zip>596-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Takatsuki</city>
        <state>Osaka</state>
        <zip>569-1096</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toyonaka</city>
        <state>Osaka</state>
        <zip>560-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yao</city>
        <state>Osaka</state>
        <zip>581-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hanyu</city>
        <state>Saitama</state>
        <zip>348-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kasukage</city>
        <state>Saitama</state>
        <zip>344-0035</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kitamoto</city>
        <state>Saitama</state>
        <zip>364-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokorozawa</city>
        <state>Saitama</state>
        <zip>359-1141</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokorozawa</city>
        <state>Saitama</state>
        <zip>359-1142</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wako</city>
        <state>Saitama</state>
        <zip>351-0102</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kusatsu</city>
        <state>Shiga</state>
        <zip>525-8585</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fujinomiya</city>
        <state>Shizuoka</state>
        <zip>418-0076</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuroi</city>
        <state>Shizuoka</state>
        <zip>437-0061</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamamatsu</city>
        <state>Shizuoka</state>
        <zip>432-8580</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamamatsu</city>
        <state>Shizuoka</state>
        <zip>433-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iwata</city>
        <state>Shizuoka</state>
        <zip>438-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shimada</city>
        <state>Shizuoka</state>
        <zip>427-8502</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Naruto</city>
        <state>Tokushima</state>
        <zip>772-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edogawa-ku</city>
        <state>Tokyo</state>
        <zip>133-0052</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hachioji</city>
        <state>Tokyo</state>
        <zip>192-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Higashikurume</city>
        <state>Tokyo</state>
        <zip>203-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Itabashi-ku</city>
        <state>Tokyo</state>
        <zip>173-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Itabashi-ku</city>
        <state>Tokyo</state>
        <zip>175-0082</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Meguro-ku</city>
        <state>Tokyo</state>
        <zip>153-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ota-ku</city>
        <state>Tokyo</state>
        <zip>145-0065</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shibuya-ku</city>
        <state>Tokyo</state>
        <zip>150-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>141-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>162-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Higashikawada</city>
        <state>Yamagata</state>
        <zip>999-7782</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shimonoseki</city>
        <state>Yamaguchi</state>
        <zip>750-0061</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shunan</city>
        <state>Yamaguchi</state>
        <zip>745-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukui</city>
        <zip>910-0067</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <zip>810-8563</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <zip>811-0213</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <zip>813-0044</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <zip>814-0180</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gifu</city>
        <zip>500-8225</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kagoshima</city>
        <zip>891-0116</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kumamoto</city>
        <zip>860-0008</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyoto</city>
        <zip>602-8026</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagasaki</city>
        <zip>850-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oita</city>
        <zip>870-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oita</city>
        <zip>870-0192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oita</city>
        <zip>870-0263</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oita</city>
        <zip>870-0917</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Okayama</city>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Okayama</city>
        <zip>700-8607</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Okinawa</city>
        <zip>904-8585</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <zip>530-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <zip>530-8480</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <zip>537-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <zip>540-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <zip>558-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <zip>558-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shizuoka</city>
        <zip>421-0193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shizuoka</city>
        <zip>422-8527</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shizuoka</city>
        <zip>424-8636</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokushima</city>
        <zip>770-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tottori</city>
        <zip>689-0203</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toyama</city>
        <zip>930-0194</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wakayama</city>
        <zip>640-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <results_reference>
    <citation>Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iwamoto K, Tajiri M; J-ROCKET AF study investigators. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study –. Circ J. 2012;76(9):2104-11. Epub 2012 Jun 5.</citation>
    <PMID>22664783</PMID>
  </results_reference>
  <results_reference>
    <citation>Chan MY, Lin M, Lucas J, Moseley A, Thompson JW, Cyr D, Ueda H, Kajikawa M, Ortel TL, Becker RC. Plasma proteomics of patients with non-valvular atrial fibrillation on chronic anti-coagulation with warfarin or a direct factor Xa inhibitor. Thromb Haemost. 2012 Dec;108(6):1180-91. doi: 10.1160/TH12-05-0310. Epub 2012 Oct 10.</citation>
    <PMID>23052711</PMID>
  </results_reference>
  <results_reference>
    <citation>Tanahashi N, Hori M, Matsumoto M, Momomura S, Uchiyama S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iwamoto K, Tajiri M; J-ROCKET AF Study Investigators. Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation for the secondary prevention of stroke: a subgroup analysis of J-ROCKET AF. J Stroke Cerebrovasc Dis. 2013 Nov;22(8):1317-25. doi: 10.1016/j.jstrokecerebrovasdis.2012.12.010. Epub 2013 Jan 22.</citation>
    <PMID>23352688</PMID>
  </results_reference>
  <results_reference>
    <citation>Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iwamoto K, Tajiri M; J-ROCKET AF study investigators. Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation: subanalysis of J-ROCKET AF for patients with moderate renal impairment. Circ J. 2013;77(3):632-8. Epub 2012 Dec 8.</citation>
    <PMID>23229461</PMID>
  </results_reference>
  <results_reference>
    <citation>Tanigawa T, Kaneko M, Hashizume K, Kajikawa M, Ueda H, Tajiri M, Paolini JF, Mueck W. Model-based dose selection for phase III rivaroxaban study in Japanese patients with non-valvular atrial fibrillation. Drug Metab Pharmacokinet. 2013;28(1):59-70. Epub 2012 Jul 17.</citation>
    <PMID>22813718</PMID>
  </results_reference>
  <results_reference>
    <citation>Kaneko M, Tanigawa T, Hashizume K, Kajikawa M, Tajiri M, Mueck W. Confirmation of model-based dose selection for a Japanese phase III study of rivaroxaban in non-valvular atrial fibrillation patients. Drug Metab Pharmacokinet. 2013;28(4):321-31. Epub 2013 Jan 22.</citation>
    <PMID>23337693</PMID>
  </results_reference>
  <results_reference>
    <citation>Matsumoto M, Hori M, Tanahashi N, Momomura S, Uchiyama S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iekushi K, Yamanaka S, Tajiri M; J-ROCKET AF Study Investigators. Rivaroxaban versus warfarin in Japanese patients with non-valvular atrial fibrillation in relation to hypertension: a subgroup analysis of the J-ROCKET AF trial. Hypertens Res. 2014 May;37(5):457-62. doi: 10.1038/hr.2014.1. Epub 2014 Jan 30.</citation>
    <PMID>24477179</PMID>
  </results_reference>
  <results_reference>
    <citation>Uchiyama S, Hori M, Matsumoto M, Tanahashi N, Momomura S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iekushi K, Yamanaka S, Tajiri M; J-ROCKET AF Study Investigators. Net clinical benefit of rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation: a subgroup analysis of J-ROCKET AF. J Stroke Cerebrovasc Dis. 2014 May-Jun;23(5):1142-7. doi: 10.1016/j.jstrokecerebrovasdis.2013.10.001. Epub 2013 Nov 1.</citation>
    <PMID>24189454</PMID>
  </results_reference>
  <results_reference>
    <citation>Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iekushi K, Yamanaka S, Tajiri M; J-ROCKET AF Study Investigators. Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation in relation to the CHADS2 score: a subgroup analysis of the J-ROCKET AF trial. J Stroke Cerebrovasc Dis. 2014 Feb;23(2):379-83. doi: 10.1016/j.jstrokecerebrovasdis.2013.07.021. Epub 2013 Aug 15.</citation>
    <PMID>23954611</PMID>
  </results_reference>
  <results_reference>
    <citation>Hori M, Kajikawa M. The J-ROCKET AF Study: a matter of ethnicity or a matter of weight? Reply. Circ J. 2013;77(10):2637. Epub 2013 Aug 1.</citation>
    <PMID>23903065</PMID>
  </results_reference>
  <results_reference>
    <citation>Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iekushi K, Yamanaka S, Tajiri M; J-ROCKET AF Study Investigators. Rivaroxaban vs. warfarin in Japanese patients with non-valvular atrial fibrillation in relation to age. Circ J. 2014;78(6):1349-56. Epub 2014 Apr 7.</citation>
    <PMID>24705469</PMID>
  </results_reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2007</study_first_submitted>
  <study_first_submitted_qc>June 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2007</study_first_posted>
  <results_first_submitted>March 28, 2012</results_first_submitted>
  <results_first_submitted_qc>March 28, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 19, 2012</results_first_posted>
  <last_update_submitted>April 1, 2015</last_update_submitted>
  <last_update_submitted_qc>April 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BAY59-7939</keyword>
  <keyword>Rivaroxaban</keyword>
  <keyword>Non-Valvular Atrial Fibrillation</keyword>
  <keyword>Japanese Patients</keyword>
  <keyword>Phase III</keyword>
  <keyword>12620</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first participant entered the study on 08 Jun 2007, and the last participant completed the study on 19 Jan 2010. The study was conducted at 167 centers in Japan. 164 study centers enrolled at least 1 participant.</recruitment_details>
      <pre_assignment_details>In total, 1439 participants were screened for study eligibility; 159 participants were screening failures and were not randomized. Therefore, 1280 participants (640 in each group) were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Rivaroxaban (Xarelto, BAY59-7939)</title>
          <description>Participants received once daily (OD) a rivaroxaban 15 mg tablet and a warfarin placebo tablet during the double-blind treatment period</description>
        </group>
        <group group_id="P2">
          <title>Warfarin</title>
          <description>Participants received OD a warfarin potassium tablet and a rivaroxaban placebo tablet during the double-blind treatment period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-blind (DB) Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="640"/>
                <participants group_id="P2" count="640"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Started Treatment</title>
              <participants_list>
                <participants group_id="P1" count="639">Safety population</participants>
                <participants group_id="P2" count="639">Safety population</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="480"/>
                <participants group_id="P2" count="468"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="160"/>
                <participants group_id="P2" count="172"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Clinical Endpoint Reached</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliant with Study Medication</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Driven Decision Point</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site Closed by Investigator</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site Closed by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Drop out before Treatment Start</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow-up (FU) Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="639">All treated participants were to enter FU period, whether or not they completed the DB period</participants>
                <participants group_id="P2" count="639">All treated participants were to enter FU period, whether or not they completed the DB period</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Entered FU and Valid for Safety</title>
              <participants_list>
                <participants group_id="P1" count="628">Safety population</participants>
                <participants group_id="P2" count="630">Safety population</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="610"/>
                <participants group_id="P2" count="616"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Clinical Endpoint Reached</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rivaroxaban (Xarelto, BAY59-7939)</title>
          <description>Participants received once daily (OD) a rivaroxaban 15 mg tablet and a warfarin placebo tablet during the double-blind treatment period</description>
        </group>
        <group group_id="B2">
          <title>Warfarin</title>
          <description>Participants received OD a warfarin potassium tablet and a rivaroxaban placebo tablet during the double-blind treatment period</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="640"/>
            <count group_id="B2" value="640"/>
            <count group_id="B3" value="1280"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.0" spread="8.3"/>
                    <measurement group_id="B2" value="71.2" spread="7.9"/>
                    <measurement group_id="B3" value="71.1" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="140"/>
                    <measurement group_id="B3" value="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="530"/>
                    <measurement group_id="B2" value="500"/>
                    <measurement group_id="B3" value="1030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CL(CR) [creatinine clearance]</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;50 mL/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="141"/>
                    <measurement group_id="B2" value="143"/>
                    <measurement group_id="B3" value="284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50 to &lt;80 mL/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="329"/>
                    <measurement group_id="B2" value="329"/>
                    <measurement group_id="B3" value="658"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥80 mL/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170"/>
                    <measurement group_id="B2" value="168"/>
                    <measurement group_id="B3" value="338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Event Rate of the Composite Endpoint of Adjudicated Major Bleeding or Adjudicated Non-major Clinically Relevant Bleeding</title>
        <description>Major bleeding: clinically overt bleeding (COB) associated with a fall in hemoglobin ≥2 g/dL, leading to transfusion ≥2 units of packed red blood cells or whole blood, occurring in a critical site or contributing to death. Non-major clinically relevant bleeding: COB that does not meet the definition of major bleeding, but requires medical intervention or unscheduled contact with the physician, (temporary) discontinuation of the study treatment, discomfort to the subject such as pain, or impairment of activities of daily life.</description>
        <time_frame>Up to 2 days after the last dose</time_frame>
        <population>The safety analysis population consisted of randomized participants who took at least one dose of study treatment (639 in each treatment group).</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban (Xarelto, BAY59-7939)</title>
            <description>Participants received once daily (OD) a rivaroxaban 15 mg tablet and a warfarin placebo tablet during the double-blind treatment period</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Participants received OD a warfarin potassium tablet and a rivaroxaban placebo tablet during the double-blind treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Event Rate of the Composite Endpoint of Adjudicated Major Bleeding or Adjudicated Non-major Clinically Relevant Bleeding</title>
          <description>Major bleeding: clinically overt bleeding (COB) associated with a fall in hemoglobin ≥2 g/dL, leading to transfusion ≥2 units of packed red blood cells or whole blood, occurring in a critical site or contributing to death. Non-major clinically relevant bleeding: COB that does not meet the definition of major bleeding, but requires medical intervention or unscheduled contact with the physician, (temporary) discontinuation of the study treatment, discomfort to the subject such as pain, or impairment of activities of daily life.</description>
          <population>The safety analysis population consisted of randomized participants who took at least one dose of study treatment (639 in each treatment group).</population>
          <units>Events per 100 patient-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="639"/>
                <count group_id="O2" value="639"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.04"/>
                    <measurement group_id="O2" value="16.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin of 2.0</non_inferiority_desc>
            <p_value>0.025</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.42</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event Rate of the Composite Endpoint of Adjudicated Stroke and Non-central Nervous System (CNS) Systemic Embolism</title>
        <description>This is the principal efficacy endpoint. Stroke included hemorrhagic, ischemic infarction and unknown. Arterial emboli in the following areas were &quot;non-CNS systemic embolism”: peripheral arterial in the upper and lower extremities, renal, mesenteric, splenic, hepatic, ocular/retinal and others. Pulmonary embolism or myocardial infarction was excluded.</description>
        <time_frame>Up to 2 days after the last dose</time_frame>
        <population>The per-protocol analysis population consisted of randomized participants excluding those who had specific pre-defined major protocol deviations (637 in each treatment group).</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban (Xarelto, BAY59-7939)</title>
            <description>Participants received once daily (OD) a rivaroxaban 15 mg tablet and a warfarin placebo tablet during the double-blind treatment period</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Participants received OD a warfarin potassium tablet and a rivaroxaban placebo tablet during the double-blind treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Event Rate of the Composite Endpoint of Adjudicated Stroke and Non-central Nervous System (CNS) Systemic Embolism</title>
          <description>This is the principal efficacy endpoint. Stroke included hemorrhagic, ischemic infarction and unknown. Arterial emboli in the following areas were &quot;non-CNS systemic embolism”: peripheral arterial in the upper and lower extremities, renal, mesenteric, splenic, hepatic, ocular/retinal and others. Pulmonary embolism or myocardial infarction was excluded.</description>
          <population>The per-protocol analysis population consisted of randomized participants excluding those who had specific pre-defined major protocol deviations (637 in each treatment group).</population>
          <units>Events per 100 patient-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="637"/>
                <count group_id="O2" value="637"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.26"/>
                    <measurement group_id="O2" value="2.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.24</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event Rate of the Composite Endpoint of Adjudicated Stroke, Non-CNS Systemic Embolism, and Vascular Death</title>
        <description>Stroke included hemorrhagic, ischemic infarction and unknown. Arterial emboli in the following areas were &quot;non-CNS systemic embolism”: peripheral arterial in the upper and lower extremities, renal, mesenteric, splenic, hepatic, ocular/retinal and others. Pulmonary embolism or myocardial infarction was excluded. Any death that was not clearly non-vascular.</description>
        <time_frame>Up to 2 days after the last dose</time_frame>
        <population>The per-protocol analysis population consisted of randomized participants excluding those who had specific pre-defined major protocol deviations (637 in each treatment group).</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban (Xarelto, BAY59-7939)</title>
            <description>Participants received once daily (OD) a rivaroxaban 15 mg tablet and a warfarin placebo tablet during the double-blind treatment period</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Participants received OD a warfarin potassium tablet and a rivaroxaban placebo tablet during the double-blind treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Event Rate of the Composite Endpoint of Adjudicated Stroke, Non-CNS Systemic Embolism, and Vascular Death</title>
          <description>Stroke included hemorrhagic, ischemic infarction and unknown. Arterial emboli in the following areas were &quot;non-CNS systemic embolism”: peripheral arterial in the upper and lower extremities, renal, mesenteric, splenic, hepatic, ocular/retinal and others. Pulmonary embolism or myocardial infarction was excluded. Any death that was not clearly non-vascular.</description>
          <population>The per-protocol analysis population consisted of randomized participants excluding those who had specific pre-defined major protocol deviations (637 in each treatment group).</population>
          <units>Events per 100 patient-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="637"/>
                <count group_id="O2" value="637"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83"/>
                    <measurement group_id="O2" value="2.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.34</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event Rate of the Composite Endpoint of Adjudicated Stroke, Non-CNS Systemic Embolism, Myocardial Infarction, and Vascular Death</title>
        <description>Stroke included hemorrhagic, ischemic infarction and unknown. Arterial emboli in the following areas were &quot;non-CNS systemic embolism”: peripheral arterial in the upper and lower extremities, renal, mesenteric, splenic, hepatic, ocular/retinal and others. Pulmonary embolism or myocardial infarction was excluded. Myocardial infarction: assessed based on either cardiac biomarkers, new abnormal Q waves appeared on electrocardiogram for ≥2 leads, or autopsy confirmation. Any death that was not clearly non-vascular.</description>
        <time_frame>Up to 2 days after the last dose</time_frame>
        <population>The per-protocol analysis population consisted of randomized participants excluding those who had specific pre-defined major protocol deviations (637 in each treatment group).</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban (Xarelto, BAY59-7939)</title>
            <description>Participants received once daily (OD) a rivaroxaban 15 mg tablet and a warfarin placebo tablet during the double-blind treatment period</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Participants received OD a warfarin potassium tablet and a rivaroxaban placebo tablet during the double-blind treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Event Rate of the Composite Endpoint of Adjudicated Stroke, Non-CNS Systemic Embolism, Myocardial Infarction, and Vascular Death</title>
          <description>Stroke included hemorrhagic, ischemic infarction and unknown. Arterial emboli in the following areas were &quot;non-CNS systemic embolism”: peripheral arterial in the upper and lower extremities, renal, mesenteric, splenic, hepatic, ocular/retinal and others. Pulmonary embolism or myocardial infarction was excluded. Myocardial infarction: assessed based on either cardiac biomarkers, new abnormal Q waves appeared on electrocardiogram for ≥2 leads, or autopsy confirmation. Any death that was not clearly non-vascular.</description>
          <population>The per-protocol analysis population consisted of randomized participants excluding those who had specific pre-defined major protocol deviations (637 in each treatment group).</population>
          <units>Events per 100 patient-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="637"/>
                <count group_id="O2" value="637"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.18"/>
                    <measurement group_id="O2" value="2.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.41</ci_lower_limit>
            <ci_upper_limit>1.34</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event Rate of Stroke</title>
        <description>All events were adjudicated and confirmed by a central independent committee blinded to treatment. Stroke included hemorrhagic (Stroke with local collections of intraparenchymal blood. Subarachnoid hemorrhage, subdural hemorrhage, and epidural hemorrhage were excluded.), ischemic infarction (Stroke without focal collection of intracranial blood) and unknown (No imaging data and anatomic findings were available.).</description>
        <time_frame>Up to 2 days after the last dose</time_frame>
        <population>The per-protocol analysis population consisted of randomized participants excluding those who had specific pre-defined major protocol deviations (637 in each treatment group).</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban (Xarelto, BAY59-7939)</title>
            <description>Participants received once daily (OD) a rivaroxaban 15 mg tablet and a warfarin placebo tablet during the double-blind treatment period</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Participants received OD a warfarin potassium tablet and a rivaroxaban placebo tablet during the double-blind treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Event Rate of Stroke</title>
          <description>All events were adjudicated and confirmed by a central independent committee blinded to treatment. Stroke included hemorrhagic (Stroke with local collections of intraparenchymal blood. Subarachnoid hemorrhage, subdural hemorrhage, and epidural hemorrhage were excluded.), ischemic infarction (Stroke without focal collection of intracranial blood) and unknown (No imaging data and anatomic findings were available.).</description>
          <population>The per-protocol analysis population consisted of randomized participants excluding those who had specific pre-defined major protocol deviations (637 in each treatment group).</population>
          <units>Events per 100 patient-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="637"/>
                <count group_id="O2" value="637"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15"/>
                    <measurement group_id="O2" value="2.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.22</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event Rate of Non-CNS Systemic Embolism</title>
        <description>All events were adjudicated and confirmed by a central independent committee blinded to treatment. Non-CNS systemic embolism was abrupt vascular insufficiency associated with clinical or radiological evidence of arterial occlusion in the absence of other likely mechanisms (such as trauma, atherosclerosis, and instrumentation). Arterial emboli in the following areas were &quot;non-CNS systemic embolism”: peripheral arterial in the upper and lower extremities, renal, mesenteric, splenic, hepatic, ocular/retinal and others. Pulmonary embolism or myocardial infarction was excluded from this category.</description>
        <time_frame>Up to 2 days after the last dose</time_frame>
        <population>The per-protocol analysis population consisted of randomized participants excluding those who had specific pre-defined major protocol deviations (637 in each treatment group).</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban (Xarelto, BAY59-7939)</title>
            <description>Participants received once daily (OD) a rivaroxaban 15 mg tablet and a warfarin placebo tablet during the double-blind treatment period</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Participants received OD a warfarin potassium tablet and a rivaroxaban placebo tablet during the double-blind treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Event Rate of Non-CNS Systemic Embolism</title>
          <description>All events were adjudicated and confirmed by a central independent committee blinded to treatment. Non-CNS systemic embolism was abrupt vascular insufficiency associated with clinical or radiological evidence of arterial occlusion in the absence of other likely mechanisms (such as trauma, atherosclerosis, and instrumentation). Arterial emboli in the following areas were &quot;non-CNS systemic embolism”: peripheral arterial in the upper and lower extremities, renal, mesenteric, splenic, hepatic, ocular/retinal and others. Pulmonary embolism or myocardial infarction was excluded from this category.</description>
          <population>The per-protocol analysis population consisted of randomized participants excluding those who had specific pre-defined major protocol deviations (637 in each treatment group).</population>
          <units>Events per 100 patient-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="637"/>
                <count group_id="O2" value="637"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11"/>
                    <measurement group_id="O2" value="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.06</ci_lower_limit>
            <ci_upper_limit>15.85</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event Rate of Myocardial Infarction</title>
        <description>All events were adjudicated and confirmed by a central independent committee blinded to treatment. Myocardial infarction was assessed based on either cardiac bio-markers (troponin I, troponin T, or creatine kinase-muscle and brain subunit isozyme), new abnormal Q waves appeared on ECG for 2 or more leads, or autopsy confirmation.</description>
        <time_frame>Up to 2 days after the last dose</time_frame>
        <population>The per-protocol analysis population consisted of randomized participants excluding those who had specific pre-defined major protocol deviations (637 in each treatment group).</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban (Xarelto, BAY59-7939)</title>
            <description>Participants received once daily (OD) a rivaroxaban 15 mg tablet and a warfarin placebo tablet during the double-blind treatment period</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Participants received OD a warfarin potassium tablet and a rivaroxaban placebo tablet during the double-blind treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Event Rate of Myocardial Infarction</title>
          <description>All events were adjudicated and confirmed by a central independent committee blinded to treatment. Myocardial infarction was assessed based on either cardiac bio-markers (troponin I, troponin T, or creatine kinase-muscle and brain subunit isozyme), new abnormal Q waves appeared on ECG for 2 or more leads, or autopsy confirmation.</description>
          <population>The per-protocol analysis population consisted of randomized participants excluding those who had specific pre-defined major protocol deviations (637 in each treatment group).</population>
          <units>Events per 100 patient-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="637"/>
                <count group_id="O2" value="637"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34"/>
                    <measurement group_id="O2" value="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.30</ci_lower_limit>
            <ci_upper_limit>28.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event Rate of Vascular Death</title>
        <description>All events were adjudicated and confirmed by a central independent committee blinded to treatment. Any death that was not clearly non-vascular (e.g., deaths due to spontaneous bleeding, myocardial infarction, stroke, cardiac failure, and arrhythmia)</description>
        <time_frame>Up to 2 days after the last dose</time_frame>
        <population>The per-protocol analysis population consisted of randomized participants excluding those who had specific pre-defined major protocol deviations (637 in each treatment group).</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban (Xarelto, BAY59-7939)</title>
            <description>Participants received once daily (OD) a rivaroxaban 15 mg tablet and a warfarin placebo tablet during the double-blind treatment period</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Participants received OD a warfarin potassium tablet and a rivaroxaban placebo tablet during the double-blind treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Event Rate of Vascular Death</title>
          <description>All events were adjudicated and confirmed by a central independent committee blinded to treatment. Any death that was not clearly non-vascular (e.g., deaths due to spontaneous bleeding, myocardial infarction, stroke, cardiac failure, and arrhythmia)</description>
          <population>The per-protocol analysis population consisted of randomized participants excluding those who had specific pre-defined major protocol deviations (637 in each treatment group).</population>
          <units>Events per 100 patient-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="637"/>
                <count group_id="O2" value="637"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69"/>
                    <measurement group_id="O2" value="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>14.70</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event Rate of Stroke With Serious Residual Disability</title>
        <description>All events were adjudicated and confirmed by a central independent committee blinded to treatment. A stroke was considered disabling if the participant’s modified Rankin score was between 3 and 5, inclusive.</description>
        <time_frame>Up to 2 days after the last dose</time_frame>
        <population>The per-protocol analysis population consisted of randomized participants excluding those who had specific pre-defined major protocol deviations (637 in each treatment group).</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban (Xarelto, BAY59-7939)</title>
            <description>Participants received once daily (OD) a rivaroxaban 15 mg tablet and a warfarin placebo tablet during the double-blind treatment period</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Participants received OD a warfarin potassium tablet and a rivaroxaban placebo tablet during the double-blind treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Event Rate of Stroke With Serious Residual Disability</title>
          <description>All events were adjudicated and confirmed by a central independent committee blinded to treatment. A stroke was considered disabling if the participant’s modified Rankin score was between 3 and 5, inclusive.</description>
          <population>The per-protocol analysis population consisted of randomized participants excluding those who had specific pre-defined major protocol deviations (637 in each treatment group).</population>
          <units>Events per 100 patient-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="637"/>
                <count group_id="O2" value="637"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57"/>
                    <measurement group_id="O2" value="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.16</ci_lower_limit>
            <ci_upper_limit>1.40</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event Rate of All-cause Death</title>
        <description>All events were adjudicated and confirmed by a central independent committee blinded to treatment. All-cause death included vascular death and non-vascular death.</description>
        <time_frame>Up to 2 days after the last dose</time_frame>
        <population>The per-protocol analysis population consisted of randomized participants excluding those who had specific pre-defined major protocol deviations (637 in each treatment group).</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban (Xarelto, BAY59-7939)</title>
            <description>Participants received once daily (OD) a rivaroxaban 15 mg tablet and a warfarin placebo tablet during the double-blind treatment period</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Participants received OD a warfarin potassium tablet and a rivaroxaban placebo tablet during the double-blind treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Event Rate of All-cause Death</title>
          <description>All events were adjudicated and confirmed by a central independent committee blinded to treatment. All-cause death included vascular death and non-vascular death.</description>
          <population>The per-protocol analysis population consisted of randomized participants excluding those who had specific pre-defined major protocol deviations (637 in each treatment group).</population>
          <units>Events per 100 patient-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="637"/>
                <count group_id="O2" value="637"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80"/>
                    <measurement group_id="O2" value="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.43</ci_lower_limit>
            <ci_upper_limit>4.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event Rate of Adjudicated Major Bleeding</title>
        <description>All events were adjudicated and confirmed by a central independent committee blinded to treatment. Major bleeding was clinically overt bleeding associated with a fall in hemoglobin of 2 g/dL or higher, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death.</description>
        <time_frame>Up to 2 days after the last dose</time_frame>
        <population>The safety analysis population consisted of randomized participants who took at least one dose of study treatment (639 in each treatment group).</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban (Xarelto, BAY59-7939)</title>
            <description>Participants received once daily (OD) a rivaroxaban 15 mg tablet and a warfarin placebo tablet during the double-blind treatment period</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Participants received OD a warfarin potassium tablet and a rivaroxaban placebo tablet during the double-blind treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Event Rate of Adjudicated Major Bleeding</title>
          <description>All events were adjudicated and confirmed by a central independent committee blinded to treatment. Major bleeding was clinically overt bleeding associated with a fall in hemoglobin of 2 g/dL or higher, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death.</description>
          <population>The safety analysis population consisted of randomized participants who took at least one dose of study treatment (639 in each treatment group).</population>
          <units>Events per 100 patient-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="639"/>
                <count group_id="O2" value="639"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00"/>
                    <measurement group_id="O2" value="3.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>1.43</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event Rate Adjudicated Non-major Clinically Relevant Bleeding</title>
        <description>All events were adjudicated and confirmed by a central independent committee blinded to treatment. Non-major clinically relevant bleeding was clinically overt bleeding that does not meet the definition of major bleeding, but requires medical intervention or unscheduled contact with the physician, (temporary) discontinuation of the study treatment, discomfort to the subject such as pain, or impairment of activities of daily life.</description>
        <time_frame>Up to 2 days after the last dose</time_frame>
        <population>The safety analysis population consisted of randomized participants who took at least one dose of study treatment (639 in each treatment group).</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban (Xarelto, BAY59-7939)</title>
            <description>Participants received once daily (OD) a rivaroxaban 15 mg tablet and a warfarin placebo tablet during the double-blind treatment period</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Participants received OD a warfarin potassium tablet and a rivaroxaban placebo tablet during the double-blind treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Event Rate Adjudicated Non-major Clinically Relevant Bleeding</title>
          <description>All events were adjudicated and confirmed by a central independent committee blinded to treatment. Non-major clinically relevant bleeding was clinically overt bleeding that does not meet the definition of major bleeding, but requires medical intervention or unscheduled contact with the physician, (temporary) discontinuation of the study treatment, discomfort to the subject such as pain, or impairment of activities of daily life.</description>
          <population>The safety analysis population consisted of randomized participants who took at least one dose of study treatment (639 in each treatment group).</population>
          <units>Events per 100 patient-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="639"/>
                <count group_id="O2" value="639"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.42"/>
                    <measurement group_id="O2" value="12.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.56</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Reporting Group (RG) 1 + 2: Safety data collected start with the first dose of study drug up to 2 days after the last dose; Reporting Group (RG) 3 + 4: Safety data collected from last dose plus 2 days to end of trial.</time_frame>
      <desc>RG3: During follow-up period, participants could be transitioned from study drug to an open-label warfarin or other appropriate therapy.</desc>
      <group_list>
        <group group_id="E1">
          <title>RG1: Rivaroxaban Double-blind (DB) Period</title>
          <description>Participants orally administered a rivaroxaban 15 mg tablet (a 10 mg tablet for participants with creatinine clearance of 30 to 49 mL/min, inclusive, at screening) and a warfarin placebo tablet once daily (OD) during the double-blind treatment period. Safety data collected start with the first dose of study drug up to 2 days after the last dose</description>
        </group>
        <group group_id="E2">
          <title>RG2: Warfarin DB Period</title>
          <description>Participants orally administered a warfarin potassium tablet and a rivaroxaban placebo tablet OD during the double-blind treatment period. Safety data collected start with the first dose of study drug up to 2 days after the last dose</description>
        </group>
        <group group_id="E3">
          <title>RG3: Rivaroxaban Follow-up (FU) Period</title>
          <description>Participants orally administered a rivaroxaban 15 mg tablet (a 10 mg tablet for participants with creatinine clearance of 30 to 49 mL/min, inclusive, at screening) and a warfarin placebo tablet once daily (OD) during the double-blind treatment period. Safety data collected from last dose plus 2 days to end of trial</description>
        </group>
        <group group_id="E4">
          <title>RG4: Warfarin FU Period</title>
          <description>Participants orally administered a warfarin potassium tablet and a rivaroxaban placebo tablet OD during the double-blind treatment period. Safety data collected from last dose plus 2 days to end of trial</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="151" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="155" subjects_at_risk="639"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="628"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="630"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="639"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Hypoprothrombinaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="628"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="639"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="639"/>
                <counts group_id="E2" events="18" subjects_affected="11" subjects_at_risk="639"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="628"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="639"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="639"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="628"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Cor pulmonale</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Auditory meatus external erosion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="639"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Macular hole</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Anal polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="639"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="639"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Mouth haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Periodontal disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Tooth loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Mechanical ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="639"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="628"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Meningitis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="639"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="639"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="628"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="628"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Enterocolitis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Infective spondylitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Accidental exposure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="639"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Spinal cord injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Spinal cord injury cervical</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Therapeutic agent toxicity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Coronary artery restenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Ligament injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Hypoproteinaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Chondrocalcinosis pyrophosphate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Compartment syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="628"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="639"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="628"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Malignant ascites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Metastases to neck</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Nasal sinus cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer stage unspecified</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Large intestine carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="628"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="628"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="630"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain stem haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Cholinergic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="639"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Facial palsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Haemorrhagic cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="628"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Hypertensive encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="628"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Vertebral artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Carotid artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Thalamus haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Putamen haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="639"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="639"/>
                <counts group_id="E3" events="12" subjects_affected="10" subjects_at_risk="628"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Postresuscitation encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychosomatic disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Renal embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="639"/>
                <counts group_id="E2" events="5" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Status asthmaticus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Bronchial haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Haemorrhage subcutaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis obliterans</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="639"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="474" subjects_at_risk="639"/>
                <counts group_id="E2" subjects_affected="470" subjects_at_risk="639"/>
                <counts group_id="E3" subjects_affected="73" subjects_at_risk="628"/>
                <counts group_id="E4" subjects_affected="61" subjects_at_risk="630"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="39" subjects_affected="36" subjects_at_risk="639"/>
                <counts group_id="E2" events="35" subjects_affected="29" subjects_at_risk="639"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="628"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="630"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" events="32" subjects_affected="26" subjects_at_risk="639"/>
                <counts group_id="E2" events="57" subjects_affected="42" subjects_at_risk="639"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="628"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="630"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="46" subjects_affected="38" subjects_at_risk="639"/>
                <counts group_id="E2" events="40" subjects_affected="32" subjects_at_risk="639"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="628"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" events="32" subjects_affected="28" subjects_at_risk="639"/>
                <counts group_id="E2" events="35" subjects_affected="34" subjects_at_risk="639"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="628"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="71" subjects_affected="57" subjects_at_risk="639"/>
                <counts group_id="E2" events="47" subjects_affected="40" subjects_at_risk="639"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="628"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" events="72" subjects_affected="54" subjects_at_risk="639"/>
                <counts group_id="E2" events="38" subjects_affected="31" subjects_at_risk="639"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="628"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="630"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="378" subjects_affected="206" subjects_at_risk="639"/>
                <counts group_id="E2" events="412" subjects_affected="232" subjects_at_risk="639"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="628"/>
                <counts group_id="E4" events="16" subjects_affected="15" subjects_at_risk="630"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="82" subjects_affected="58" subjects_at_risk="639"/>
                <counts group_id="E2" events="80" subjects_affected="56" subjects_at_risk="639"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="628"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Wound haemorrhage</sub_title>
                <counts group_id="E1" events="38" subjects_affected="33" subjects_at_risk="639"/>
                <counts group_id="E2" events="31" subjects_affected="27" subjects_at_risk="639"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="628"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="630"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="48" subjects_affected="43" subjects_at_risk="639"/>
                <counts group_id="E2" events="34" subjects_affected="31" subjects_at_risk="639"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="628"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="630"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="57" subjects_affected="50" subjects_at_risk="639"/>
                <counts group_id="E2" events="60" subjects_affected="56" subjects_at_risk="639"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="628"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="630"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="29" subjects_affected="24" subjects_at_risk="639"/>
                <counts group_id="E2" events="43" subjects_affected="39" subjects_at_risk="639"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="628"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="630"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="203" subjects_affected="102" subjects_at_risk="639"/>
                <counts group_id="E2" events="86" subjects_affected="59" subjects_at_risk="639"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="628"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" events="76" subjects_affected="55" subjects_at_risk="639"/>
                <counts group_id="E2" events="102" subjects_affected="74" subjects_at_risk="639"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="628"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="630"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="50" subjects_affected="37" subjects_at_risk="639"/>
                <counts group_id="E2" events="49" subjects_affected="43" subjects_at_risk="639"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="628"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="630"/>
              </event>
              <event>
                <sub_title>Haemorrhage subcutaneous</sub_title>
                <counts group_id="E1" events="147" subjects_affected="67" subjects_at_risk="639"/>
                <counts group_id="E2" events="175" subjects_affected="79" subjects_at_risk="639"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="628"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="630"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="25" subjects_affected="24" subjects_at_risk="639"/>
                <counts group_id="E2" events="36" subjects_affected="32" subjects_at_risk="639"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="628"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="630"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>BAYER</organization>
      <email>clinical-trials-contact@bayerhealthcare.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

